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This paper is based on my 2017 Research Laureate Presentation at the Annual Scientific Meeting 
of the American Academy of Health Behavior in Tucson, Arizona. It provides a brief overview 
of the history of the smoking epidemic, and describes my work in global tobacco control, 
focusing on my experiences over the last 15 years as a co-founder and intervention director of 
the Syrian Center for Tobacco Studies (SCTS) in Aleppo, Syria. The SCTS is an NIH-funded 
research center that draws on a broad range of complementary expertise and resources from 
developed and developing nations to address the tobacco epidemic in the Arab World. The SCTS 
strives to serve as a model of scientific excellence and commitment to the health of people in the 
Middle East and beyond. Major research streams using qualitative, epidemiological, clinical lab, 
and intervention methodologies are reviewed, along with some of the successes and challenges 
encountered since the SCTS’s founding. 
 
 
*Corresponding author can be reached at: kdward@memphis.edu 
 
 
The American Academy of Health Behavior (AAHB) has been my professional home for many 
years, and it is an honor to be named the 2017 Research Laureate. My work focuses on 
preventing chronic disease, and I have “dabbled” in understanding behavioral determinants and 
intervention approaches to conditions such as metabolic syndrome and heart disease1–7 and 
osteoporosis,8–13 but my true passion throughout my career has been tobacco control, especially 
improving methods to help smokers quit. 
 The initial spark for this interest came from growing up in a family of inveterate smokers. 
We study what we’re bad at, as the old saying goes. I watched many family members – my 
father, his four siblings, and more recently my brother – struggle mightily, and too often, 
unsuccessfully, to quit. Many of them died much too young from the inevitable consequences of 
smoking – lung cancer, chronic obstructive pulmonary disease, and heart disease.  
I have been fortunate to have superb mentors throughout my career, and as an 
undergraduate at Brown University in the 1980s, my earliest mentors showed me that I could 
make tobacco control a career. Ray Niaura and David Abrams – two AAHB Research Laureates 
– were my first inspirations for this career.  Ray was a member of my undergraduate honors 
thesis committee. He and David gave me my first job in this field, working as a research assistant 
on cue reactivity studies in smokers. In the interest of full disclosure, I’ll admit that I was a social 
smoker back in those days and particularly enjoyed one job duty: In those cue reactivity studies, 
I was responsible for hooking smokers up to psychophysiological monitoring equipment, and 
after I got them comfortably situated in a small lab room, I would stroll in, take out a pack of 
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their preferred cigarette brand, and smoke it in front of them. All for science, mind you, but I 
received some personal gratification as well.  
 I took a job in the late 1980s at the Boston Veterans Administration Outpatient Clinic, 
working for Arthur J. (“Jim”) Garvey, who despite being a quintessentially grumbly Bostonian, 
is one of the kindest people I ever met. I learned a lot from him, especially about being modest, 
ethical, diligent, respectful, and generous. Jim was always willing to share the credit with his 
employees and colleagues. His knack for treating everyone, especially underlings, as colleagues 
was a powerful lesson that I’ve tried to emulate. Working for Jim, I coordinated a cohort study to 
learn about psychological and physiological changes experienced during unaided cessation.14–16 
Quitting on one’s own without help was then, and still is (despite treatment advances), the most 
common way people quit smoking. What an incredible learning experience it was to interview 
dozens of smokers multiple times over the course of their first year after a quit attempt to learn 
about their successes and challenges.  
Later, other important mentors included Scott Weiss, a Harvard pulmonologist and 
epidemiologist from whom I learned the ins and outs of conducting large-scale studies in chronic 
disease epidemiology.5–7 I moved to Memphis in 1993 to work on my PhD under Bob Klesges. 
Bob is a talented and successful smoking cessation trialist, and I learned much from him about 
how to write grants and treat tobacco addiction.17–21 We need mentors throughout our careers, 
and our own Elbert Glover has been a wonderful confidante and counselor as I have established 
myself as a health behavior researcher, sharing his wisdom with me through the tenure process, 
job searches, and academic administration positions. I owe a debt of gratitude to all these people 
as well as the many bosses, colleagues, and students I’ve worked with over the years. 
 
Scope of the Smoking Problem 
 
 The twentieth century has been called “The cigarette century.”22 Originally a small niche 
product in the latter part of the 19th century, cigarette sales began to skyrocket in the early 1900s 
and quickly replaced cigars, pipes, and chew as the preferred tobacco use method.22 The cigarette 
century was made possible by James Bonsack’s invention of a cigarette rolling machine in 
1880,23 which immediately raised output from the four cigarettes per minute that an experienced 
hand roller could produce, to 200 cigarettes per minute by even the earliest versions of 
Bonsack’s machine. Further advancements both in manufacturing and marketing led to rapid 
increases in cigarette use during the first half of the 20th century. At the zenith of smoking in the 
United States in 1965, approximately 42% of U.S. adults smoked, including more than half of 
men and one-third of women.24 Tobacco use in the United States began to decline after the 
publication of the first Surgeon General’s Report on Smoking and Health,25 which 
comprehensively laid out the evidence of smoking’s causal role in lung cancer and other 
diseases. Smoking continued to decline in the United States as more adults quit and fewer 
children began smoking. This progress occurred gradually, despite tobacco industry interference 
at every turn, and was exacted by advocacy and numerous policy changes – advertising bans, 
youth access restriction, increased taxation, and the development and widespread dissemination 
of behavioral and pharmacological cessation treatments22,23 (See Figure 1). Today, smoking rates 
are below 20% for both men and women in the United States,26 causing tobacco control to be 








Figure 1. Adult per capita cigarette consumption and major smoking and health events, United 
States, 1900–2012 (from U.S. Department of Health and Human Services, The Health 
Consequences of Smoking—50 Years of Progress: a report of the Surgeon General, Centers for 
Disease Control and Prevention, National Center for Chronic Disease Prevention and Health 
Promotion, and Office of Smoking and Health) 
 
 
 But as all health behavior researchers know, the story isn’t entirely rosy. Smoking is still 
the greatest cause of premature morbidity and mortality in the United States, killing 
approximately 480,000 people each year.30 Even worse, it has become a global epidemic. 
Currently, more than a billion people around the world smoke. Nearly five and a half million of 
them die each year prematurely due to smoking, and a significant shift has occurred, such that in 
the near future the majority of deaths will occur in developing countries. While smoking killed 
100 million people during the 20th century, it’s expected to kill ten times that number – 1 billion 
– during the current century.31 
 As an assistant professor starting a career in tobacco control in the late 1990s, my interest 
in global tobacco control was sparked by the disheartening realization that we were engaged in a 
kind of whack-a-mole game: As we reduced tobacco use in the United States and other high-
income countries, it accelerated in the developing world, with multinational tobacco companies 
rushing to open new markets and create new customers faster than our prevention and cessation 
efforts could stop this. Clearly, we are losing the game, with global tobacco use increasing 
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exponentially and 5.8 trillion cigarettes smoked around the world in 2014.32 The complicit 
tobacco industry/government strategy was expressed eloquently in 1990 by U.S. Vice President 
Dan Quayle, who famously said: “Tobacco exports should be expanded aggressively, because 
Americans are smoking less.”33 
   
Establishment of the Syrian Center for Tobacco Studies 
 
My first opportunity to become involved in global tobacco control came in June, 2001, 
when the National Institutes of Health announced a new funding opportunity to help low and 
middle-income countries build infrastructure for tobacco control research. The International 
Tobacco Health and Capacity-Building Program (ITHCBP; RFA-TW-02-005) focused on novel 
and regionally relevant work, emphasizing capacity building, training of scientists, and 
international cooperation to increase the ability of developing nations to engage in effective 
tobacco control research.34 The ITHCBP has been a sizeable commitment for NIH; they 
allocated close to $4 million for this first round and subsequently funded two more rounds, with 
a fourth round now about to be launched (RFA-TW-16-003).  
 I wanted to respond to this announcement but did not have international collaborators. 
Then one day that summer, an email appeared on the listserv of the Society for Research on 
Nicotine and Tobacco (SRNT) from a Syrian researcher by the name of Wasim Maziak, looking 
for collaborators for this funding opportunity.  
  As an aside, it is worth noting that Wasim is the hero of my story. He is an exceptionally 
bright, hard-working individual, and his journey reminds me how fortunate we are in the United 
States to have the opportunity to pursue research careers. Doing so is difficult – the work is 
tough, jobs are not plentiful, and funding is scarce. But if we want a research career, and are 
willing to work hard, we have an excellent chance of succeeding. This was not the case in Syria, 
Wasim’s homeland. He attended medical school in his hometown at the University of Aleppo. 
Syria had no doctoral training programs, so when Wasim decided he wanted to pursue a research 
career, he learned Russian and moved to Kiev to obtain a PhD in allergy/immunology. He then 
returned to Aleppo and opened a private medical practice, took a clinical faculty position at the 
medical school, and began to do research in his free time. With no culture of research at his 
university and no funding, he began collecting data on tobacco use on nights and weekends, 
recruiting his brother and wife, both physicians, as his research assistants. They were the first to 
characterize tobacco use in Syria and published several very good epidemiological studies about 
smoking prevalence and determinants among university students, low-income women, 
physicians, and high school students.35  
 With no opportunities for a research career in Syria, Wasim and his family left, and he 
took post-doctoral positions in Atlanta, then London, then Muenster, hoping for an opportunity 
to return to his homeland eventually. Wasim was working as a post-doc at the University of 
Muenster’s Institute of Epidemiology and Social Medicine when he saw the ITHCBP funding 
opportunity announcement and sent an email on the SRNT listserv to which both Tom 
Eissenberg, then an assistant professor of psychology at Virginia Commonwealth University, and 
I responded.  
 Wasim, Tom, and I started an email conversation in July of 2001 and began 
brainstorming how the three of us could work together. Developing a collaboration and writing a 
grant with strangers, entirely via email, may not seem so unusual nowadays, but in 2001 it 
seemed quite innovative! It all nearly came to a crashing end only a couple of months later. We 
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had arranged for Tom to spend a few days in Memphis to work on the grant. This would have 
been the first time that any of us had met in person. However, Tom never made it. His morning 
flight to Memphis on September 11th never left Richmond due to the terrorist attacks underway 
in New York, Washington DC, and Pennsylvania. We were stunned, like everyone, and put aside 
the grant and spent a couple of weeks figuring out how to regroup. It seemed very unlikely after 
this tragedy that the U.S. government would fund research in the Middle East, particularly in 
Syria, a country which was on the U.S. government’s list of state sponsors of terrorism. NIH’s 
Fogarty International Center was (and continues to be) very supportive, and encouraged us not to 
give up. So, we got back to work and were thrilled when our grant, “Establishment of the Syrian 
Center for Tobacco Studies,” was funded (R01 TW05962).  
The Syrian Center for Tobacco Studies (SCTS) (www.scts-sy.org) was opened in Aleppo, 
located in northern Syria near the Turkish border, in 2002. Aleppo is an ancient city, on the 
famed “Silk Road” network of trade routes between East and West, and considered to be the 
oldest continually inhabited city in the world, going back as many as 8000 years. Until the Syrian 
Civil War began in 2011, Aleppo was a thriving industrial and commercial center and was 
Syria’s largest city with a population of more than two million. Our work began nine years 
before the war and has continued in spite of it, as discussed below. 
 
Qualitative, Clinical Lab, and Epidemiological Studies 
 
  The initial goals of the SCTS were to train Syrian researchers and develop capacity in the 
Eastern Mediterranean Region (EMR) to conduct epidemiologic, clinical laboratory, and 
cessation intervention research related to local tobacco products. While cigarette use is common 
in Syria and throughout the EMR, an emerging and understudied local tobacco product that 
attracted our attention was waterpipe. Waterpipe, known colloquially by such names as hookah, 
shisha, and narghile, is a centuries-old tobacco use method, in which tobacco is heated, usually 
with charcoal, and its smoke is passed through water before inhalation36 (see Figure 2). 
Waterpipe tobacco smoking (WTS) is thought to have originated on the Indian sub-continent 
during the 16th century and found its way over the next century to Persia, Turkey, and the 
EMR.36  
 




Ward: Research Laureate Presentation
Published by New Prairie Press, 2017
 
 
 By the end of the 20th century, the popularity of WTS had dwindled, and it was favored 
mainly by older Arab men who smoked it socially in cafes. WTS was so rare that national and 
international surveys of tobacco use in the Middle East failed to inquire about it. Its popularity 
began to re-emerge, however, in the 1990s, fueled by several factors. The chief contributor was 
the invention of maassel (or Mu’essel; “asal” means honey in Arabic), a tobacco mix flavored 
with molasses or fruit. Maassel is moist (making it easier to use than older and drier types of 
waterpipe tobacco). The passage of smoke through water makes it very smooth to inhale, unlike 
the harshness of cigarettes. And it is very fragrant. These characteristics are very appealing to 
young people,37,38 who have been at the epicenter of a global spread of WTS.39,40 Despite WTS 
being associated with multiple adverse health effects,41,42 there are widespread misperceptions 
among adolescents and young adult users that it is safe, or at least safer than cigarettes.38,40,43,44 
Other contributors to the new popularity of WTS were a growing café culture in the Middle East, 
expanding internet availability, and increasing globalization that made WTS a global 
phenomenon in just two decades.36,39  
  To better understand the use of waterpipe and cigarettes in Syria, and to guide us in 
accessing relevant populations, we began our work with qualitative studies, using key informant 
interviews and focus groups.45,46 Next, clinical lab work was carried out to understand how local 
tobacco products were used. One stream of this research demonstrated WTS’s dependence 
potential, showing that smokers inhaled substantial amounts of toxicants, including nicotine, and 
experienced withdrawal symptoms during abstinence that were relieved by smoking.47–49  
 Simultaneously, we carried out a series of epidemiological studies, including the country’s 
first population-based household surveys, to understand the patterns and determinants of tobacco 
use and cessation in Aleppo. In 2004, the Aleppo Household Survey found very high rates of 
smoking, with 57% of men and 17% of women currently smoking cigarettes, and 20% and 5%, 
respectively, currently smoking waterpipe.50 Consistent with the notion that waterpipe use was a 
re-emerging strain in a global tobacco epidemic, our survey work indicated that the vast majority 
of waterpipe users, regardless of age, had initiated use after 1990, with use continuing to escalate 
during the first decade of the 21st century.51 Survey work also indicated that while there was 
considerable interest in quitting smoking, quit rates were very low.50,52 For example, only 15% of 
those who had ever smoked cigarettes had quit, which is half of the prevalence of quitting among 
U.S. smokers.26 Consistent with our clinical lab data showing that waterpipe delivered large 
amounts of nicotine and produced withdrawal symptoms,47–49 survey work indicated that many 
waterpipe users exhibited dependence symptoms. Waterpipe users often escalated the frequency 
of their use over time (consistent with tolerance), considered themselves to be “hooked,” and had 
difficulty quitting.43,52 Because WTS is not as “portable” as cigarette smoking, we found that 
heavy users were likely to engage in behavioral adaptation to ensure access to waterpipe (eg, 
owning one’s waterpipe, selecting restaurants based on whether waterpipe is available, and 
smoking mainly alone and/or at home).53,54 
 
Tobacco Intervention Trials 
 
  The qualitative, clinical lab, and epidemiological studies we conducted in Syria provided 
the foundation for the development of smoking cessation interventions, which is my primary 
research interest. This foundation was essential to our work because Syria had no infrastructure 
for smoking cessation. Medical and nursing students received no training in smoking cessation; 
6




smoking by physicians and nurses was prevalent and made them reluctant to address their 
patients’ smoking; there were no clinical practice guidelines, and neither specialty cessation 
clinics nor pharmacotherapy such as nicotine replacement or Bupropion were available.55,56 
There also was no expertise in developing and scientifically evaluating cessation interventions.  
 Our efforts to build evidence-based tobacco treatment in Syria were detailed in a recent 
paper.56 We began by using both in-country instruction and distance learning to train a small core 
group of physicians to deliver cessation interventions and to conduct randomized controlled trials 
to evaluate them. Our first effort to demonstrate our ability to intervene and evaluate was a pilot 
trial of 50 cigarette smokers who wanted to quit.57 Smokers were randomized to receive either 
brief (single session) or intensive (four sessions plus six follow up phone calls) free, behavioral 
cessation counseling delivered by a physician. Seven-day point prevalent abstinence, which was 
confirmed biochemically, at three months post-cessation was low for both the brief and intensive 
groups (16% and 4%, respectively, p = .34). Nicotine dependence predicted failure to quit, and 
important perceived barriers to quitting were believing oneself to be dependent on nicotine, not 
having access to cessation pharmacotherapy, poor social support, and smoking waterpipe. Our 
process evaluation indicated that participants were satisfied with the care they received and the 
treatment program in general, and gave us valuable information on how to modify the protocol to 
improve adherence and efficacy.56,57 
  This pilot study demonstrated our ability to train physicians to competently deliver 
evidence-based cessation treatments and conduct rigorous evaluations of treatment programs 
using randomized controlled trial methodology. Our next undertaking was to carry out an 
effectiveness trial to determine whether cessation interventions could be successfully integrated 
into Syrian primary care clinics. As noted above, our pilot study did not offer pharmacotherapy. 
This was problematic not only because smokers were highly nicotine dependent, but also 
because of a cultural expectation that medication should be received during a medical encounter. 
As a result, many participants in our pilot study were demoralized about receiving only 
behavioral treatment. While there was convincing evidence from the United States and other 
high-income countries that nicotine replacement products and Bupropion boosted quit rates,58 
these products were not available in Syria. In early 2004, as we planned this work, we met with 
Syria’s Minister of Health, Professor M. Eyad Chatty, and asked about the possibility of 
government-operated primary care clinics providing cessation medication. To offer these would 
be an expensive undertaking, and the health minister told us he wanted to see efficacy data 
collected in Syria as a first step in making these medications available. Given the large number 
of cessation pharmacotherapy trials already conducted in other countries, undertaking another 
one to replicate a well-known effect was not very interesting to us. We decided, however, that 
doing so was a political necessity if we were to have any chance of making effective cessation 
treatment available in Syria. 
 With these marching orders, our next study was a multi-site, two-arm, randomized, 
placebo-controlled trial to test the effectiveness of nicotine patch as adjunctive treatment with 
behavioral counseling in primary care settings.59–62 Four clinics were selected and clinic staffs 
were trained by physician staff members of the SCTS to make system-level changes to support 
cessation efforts (eg, having receptionists document the smoking status of all patients, and 
training physicians to briefly assess their patients’ smoking status and willingness to make a quit 
attempt). Two hundred and sixty-nine adult primary care patients who were smokers were 
enrolled and randomized to receive six weeks of treatment with nicotine or placebo patch. All 
participants received behavioral counseling from a specially trained primary care physician in the 
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clinic. Primary endpoints were biochemically confirmed prolonged abstinence (no smoking 
whatsoever after a 2-week grace period) through 12 months post-cessation (see Figure 3). Much 
to our surprise, nicotine patch did not boost quit rates over and above what could be achieved by 
behavioral counseling alone, in contrast to an extensive literature from high-income 
countries.58,63,64 The proportion of patients in the nicotine and placebo groups with prolonged 
abstinence was 21.6% and 20.0%, respectively, at end of treatment, 13.4% and 14.1% at 6 
months, and 12.7% and 11.9% at 12 months (all p-values > .75). The lack of a treatment effect 
occurred despite excellent retention and adherence to medication use and behavioral counseling, 
and expected decreases in withdrawal symptomatology among the nicotine group. These results 
need to be followed up, but this first “real world” cessation pharmacotherapy trial in a low-
income country setting suggests that medication, which often is very expensive or not available, 
may not offer a benefit beyond what can be achieved by behavioral counseling.  
 
Figure 3. CONSORT diagram for a multi-site, two-arm, randomized, placebo-controlled trial to 
test the effectiveness of nicotine patch as adjunctive treatment with behavioral counseling in 





 Given evidence generated by the SCTS that many waterpipe smokers exhibit withdrawal 
and other dependence symptoms and have difficulty quitting, we have argued that efforts are 
needed to develop and test WTS-specific cessation interventions.65,66 We conducted a pilot, two-
arm, parallel group, randomized, open-label RCT to test the efficacy of intensive behavioral 
treatment for waterpipe smokers who were interested in quitting. We adapted intervention 
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strategies from our cigarette trials.57,59 Fifty adults who smoked waterpipe three or more times 
per week for at least one year, did not smoke cigarettes, and were interested in quitting were 
randomized to receive either brief (one in-person session and three phone calls) or intensive 
(three in-person sessions and three phone calls) behavioral counseling from a trained physician 
in a clinical setting. The primary endpoint was prolonged abstinence at three months post-
cessation, biochemically confirmed. Prolonged abstinence was achieved by 30% and 44% of 
participants in the brief and intensive interventions, respectively. This difference was not 
statistically significant due to the small number of smokers enrolled in this pilot trial (p = .31), 
but provided encouraging preliminary evidence of the efficacy of this treatment approach. A 
growing number of trials are now evaluating behavioral and pharmacological treatment 
approaches for waterpipe smokers.67–69 
 
Successes and Challenges 
 
 Our work in the SCTS has been extremely rewarding, but not without its challenges. On the 
plus side, the efforts of my dedicated and hard-working colleagues over the past 15 years have 
allowed us to publish more than 120 peer-reviewed papers, participate in two WHO (World 
Health Organization) advisories on the waterpipe, be continually funded by NIH as well as 
several non-U.S. funders, establish Syria’s first institutional review board, train numerous 
researchers throughout the EMR, and receive a WHO Director General Prize and the Hamdan 
Award for the Best Medical/Research Institute in the Arab World. 
 Like our successes, our challenges have been numerous. Many of these challenges are 
common to conducting research in resource-poor environments, ranging from the relatively 
minor (keeping the electricity on when the grid is unreliable) to the major (how to pay employees 
a living wage during rampant inflation caused by the influx of Iraqi War refugees, and how to 
avoid “brain drain” and ensure that researchers have viable career paths).  
 Other challenges were specific to the tense political environment surrounding U.S./Middle 
East relationships. Syrians were suspicious of U.S. intentions, and we had to cope with spying, 
interference from government agencies, and the temporary closing of our center due to false anti-
government activities charges, which required the intervention of the Syrian ambassador to the 
United States. In theUnited States, there was not much popular support after 9/11 for using tax 
dollars to conduct research efforts in the Middle East. After the United States enacted sanctions 
in 2003 to stop Syria's alleged development of weapons of mass destruction, we had to find 
creative ways to pay our staff and keep our research operation alive. With all these challenges, 
NIH’s tireless support—both financial and in helping us navigate the web of government 
agencies and resources—was critical to our success.  
 These problems, however, pale in comparison to those resulting from the Syrian Civil War, 
which began in 2011 as part of the wider Arab Spring protests throughout the region. We were 
able to carry on our work in Syria early in the war, but Aleppo finally was engulfed. Beautiful 
Aleppo, the ancient city on the Silk Road, is now a war zone, and called “the worst place in the 
world,”70 with little food, water, or electricity. Probably at least two-thirds of its population have 
fled, been forcibly removed, or been killed. Our staff are now dispersed to other countries, and 
the SCTS continues to thrive as a “virtual” research center. Fortunately, the partnerships the 
SCTS established have allowed our work to continue despite the horrific situation in Syria. 
Studies have been conducted in neighboring Jordan71–73 and Lebanon. Presently, in Beirut, we 
are conducting the Waterpipe Dependence in Lebanese Youth (WDLY) prospective study, 
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tracking the development of nicotine dependence in a cohort of 498 adolescent cigarette and 
waterpipe smokers and those susceptible to smoking. Recently published baseline data from the 
WDLY indicate that nicotine dependence can appear within a relatively short time after 
initiation, and occurs at a lower frequency of use compared to cigarette smoking.74–76 
 The work of the SCTS continues, and we recently were funded on the fourth round of 
NIH’s International Tobacco Health and Capacity-Building Program (RFA-TW-16-003; 
1R01TW010654, W. Maziak, PI). This new project will continue some of our ongoing work, and 
expand our research partnerships in the region. Our aims are to 1) understand late nicotine 
dependence trajectories among the WDLY cohort of young waterpipe and cigarette smokers in 
Lebanon; 2) develop and test waterpipe-specific health warning labels for the Eastern 
Mediterranean Region using a mixed methods approach; 3) conduct a situational analysis in 
Tunisia and Lebanon to understand local tobacco control policy environments; and 4) train 
researchers in Tunisia and Lebanon through a mixture of didactic training and applied mentored 
research.  
 Over the past 15 years, we have often cited a Carl Sagan quote that speaks to the backdrop 
of our work in the SCTS, and this quote seems as relevant as ever in today’s turbulent world: 
“Whenever our ethnic or national prejudices are aroused, in times of scarcity, during challenges 
to national self-esteem or nerve, when we agonize about our diminished cosmic place and 
purpose, or when fanaticism is bubbling up around us--then, habits of thought familiar from 
ages past reach for the controls. The candle flame gutters. Its little pool of light trembles. 
Darkness gathers. The demons begin to stir.”77 The SCTS is our small attempt to keep the 
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